Chronic graft-versus-host disease: Implications of the National Institutes of Health consensus development project on criteria for clinical trials

Bone Marrow Transplantation

Volumn 38, Issue 10, 2006, Pages 645-651

  Pavletic, S Z ^a   Lee, S J ^b   Socie, G ^c   Vogelsang, G ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN; STEROID;

CHRONIC GRAFT VERSUS HOST DISEASE; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; HEALTH CARE ORGANIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; METHODOLOGY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; STAGING; STANDARDIZATION; TREATMENT INDICATION; TREATMENT RESPONSE; VALIDATION STUDY;

CHRONIC DISEASE; CLINICAL TRIALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGNOSIS; UNITED STATES;

EID: 33750547108     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705490     Document Type: Review

References (26)

1. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
2. Farag SS. Chronic graft-versus-host disease: Where do we go from here? Bone Marrow Transplant 2004; 33: 569-577.
3. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
4. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12: 31-47.
5. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006; 12: 126-137.
6. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266.
7. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375-396.
8. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006; 12: 491-505.
9. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
10. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-740.
12. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 664-670.
13. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-530.
14. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol 2003; 30:603-617.
15. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444-452.
16. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M et al. Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 2000; 89: 1634-1646.
17. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16:139-144.
18. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 1985; 66:69-74.
19. Brooks D, Parsons J, Tran D, Jeng B, Gorczyca B, Newton J et al. The two-minute walk test as a measure of functional capacity in cardiac surgery patients. Arch Phys Med Rehabil 2004; 85:1525-1530.
20. Eiser N, Willsher D, Dore CJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir Med 2003; 97:407-414.
21. Daughton DM, Fix AJ, Kass I, Bell CW, Patil KD. Maximum oxygen consumption and the ADAPT quality-of-life scale. Arch Phys Med Rehabil 1982; 63:620-622.
22. Ware Jr JE. SF-36 health survey update. Spine 2000; 25:3 130-3139.
23. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-483.
24. McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A et al. Quality of life measurement in bone marrow transplantation: Development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19:357-368.
25. Mitchell S, Reeve B, Cowen E, Fall-Dickson J, Gerber L, Guadagnini JP et al. Feasibility and reproducibility of the new NIH consensus criteria to evaluate response in chronic GVHD - a Pilot study. Blood 2005; 106 (Suppl 1):aBstract #3121.
26. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjogren's syndrome:a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558.